None of this is surprising — especially when at least 500,000 Brits are currently taking Mounjaro and Wegovy via private prescription. For many, the prospect of going cold turkey or forking out up to ...

Scientists at Jiangnan University in China recently found that there is a specific gut microbe known as Bacteroides vulgatus, ...

A plant compound known as berberine has been called the ‘nature’s Ozempic,' but doctor sheds a reality check if it is similar ...

Weight-loss drugs for dogs are the next big thing in pet healthcare. It’s no bad thing, says Charlotte Cripps, who ...

What started as a medical solution to diabetes has exploded into a worldwide weight-loss trend, with demand skyrocketing as ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 ...

Hims & Hers Health Inc. HIMS shares are trading lower Tuesday after GoodRx Inc. GDRX announced a collaboration with Novo ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

The company is the latest facing historic losses as pharmaceutical firms compete to develop a weight-loss pill.

Novo Nordisk announced Monday that U.S. patients can now get a month's supply of Ozempic, the blockbuster diabetes drug, for $499, for those who pay for medications on their own and don't go through ...